Home Search
drug development - search results
If you're not happy with the results, please do another search
Alzheimer’s drug slows memory decline in phase 3 trial
Henry Scowcroft from Alzheimer’s Research UK, argues that an Alzheimer’s drug, lecanemab, can slow memory decline in a phase 3 trial.
Tuberculosis drug regimens and their efficacies
Andrew Nunn, Professor of Epidemiology in the Medical Research Council Clinical Trials Unit at UCL, analyses tuberculosis drug development.
Healing benefits of honey offers alternative to antimicrobial drugs
According to researchers, the healing benefits of honey are so promising that the sweet substance may replace antimicrobial drugs.
Tuberculosis drug regimens and their efficacies
Andrew Nunn, Professor of Epidemiology in the Medical Research Council Clinical Trials Unit at UCL, analyses different tuberculosis drug development regimens.
Migraine drug can boost weight loss by suppressing appetite
Triptans, a commonly prescribed class of migraine drugs, can help with weight loss and treating obesity by suppressing appetite.
Research reveals that anti-TNF drug reverses Dupuytren’s disease
A clinical trial at Oxford University has found that a drug used for rheumatoid arthritis can reverse Dupuytren’s disease, if taken early on.
Scientists invent drug that stops the biology of fear
Tokyo researchers reveal how the biology of fear works - potentially changing how PTSD and anxiety are treated in future.
Treating multi-drug resistant tuberculosis
Andrew Nunn, Professor of Epidemiology, Medical Research Council Clinical Trials Unit at UCL, describes the first phase 3 trial of a shortened treatment for MDR-TB.
Levelling Up promises £3 billion on drug enforcement
Neighbourhood crime is at the heart of the policy, with the UK promising to cut homicide, serious violence and more by 2030.
Drug gives 34% protection against lung cancer recurrence
The NHS have gained a new drug, atezolizumab, which can give 34% protection against lung cancer recurrence or death, post-chemotherapy.
New gene-silencing drug could help with ALS
New research suggests that in suppressing a mutated ALS gene, it may be possible to delay to onset of symptoms.
Performance enhancing drugs can induce eating disorders
A study finds that performance and appearance enhancing drugs are closely linked to eating disorder symptoms in the US - especially in college-age groups.
Chemistry: Catalyst developments for organic synthesis
Prof Masahiro Kamitani from the Department of Chemistry at Kitasato University, Japan, introduces recent advances in the development of catalysts for organic synthesis and iron catalysts as alternatives for precious metal catalysts.
In scilico drug repositioning targeting SARS-CoV-2
Development of effective drugs toward COVID-19 is urgently required, and so research is being implemented with in scilico drug repositioning.
Malaria deaths reduced by 70% with vaccine and drug combination
A combination of the world’s first malaria vaccine RTS,S/AS01E and antimalarial drugs reduce child hospitalisations and death by 70%.
Using human models of brain development to understand autism
Dr Kristen Kroll from Washington University School of Medicine discusses new approaches for studying autism and other neurodevelopmental disorders by using human cellular models of brain development.
Combination of remdesivir and hep C drugs effective against COVID-19
A combination of remdesivir and drugs for hepatitis C virus (HCV) have presented strong effectiveness against COVID-19 in a new study.
The changing perspective of psychedelic drugs with a history of abuse
Jason W. Loxterkamp and Pamela J. Lein from University of California, Davis, explore the therapeutic potential of psychedelic drugs in patients with psychiatric disorders.
Polymers and polymer-based drug delivery in the treatment of dry eye disease
Professor Heather Sheardown, C20/20 Ophthalmic Materials Innovation Hub, Department of Chemical Engineering, McMaster University, explores how polymers can be used to treat dry eye disease.
Existing drugs could be used to fight COVID-19 in elderly patients
A research team at MIT have created a machine-learning strategy to identify existing drugs that could be repurposed to fight COVID-19 in elderly patients.